The Indian biopharma industry's outlook for the next 5-10 years
The Indian biopharma sector is on the cusp of a major transformation. Traditionally known for its dominance in generic drugs, the industry is now pivoting towards higher-value segments like biosimilars, vaccines, and innovative therapies. This shift is driven by evolving global healthcare needs, patent expirations of blockbuster biologics, and the industry's ambition to move up the value chain. Biosimilars represent a significant opportunity. With many biologics losing patent protection, Indian companies are well-positioned to capture a substantial share of this growing market. Their expertise in reverse engineering and cost-effective manufacturing gives them a competitive edge. However, success in this space requires substantial investments in R&D and clinical trials, as well as navigating complex regulatory pathways in developed markets. The COVID-19 pandemic has spotlighted India's vaccine manufacturing capabilities. The country's role as the "pharmacy of the ...